URGN
UroGen Pharma·NASDAQ
--
--(--)
--
--(--)
9.02 / 10
Outperform
Sentiment is high (9.02) and fund‑flow score 7.35, both positive. Analysts give a Strong Buy consensus, though only one analyst is covered with a modest 41.7% historical win rate. Overall sentiment and money flow are bullish.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-02
InstitutionD. Boral Capital
Times predicted12
Historical Win Rate41.7%
What is the analyst consensus for URGN?
- URGN holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 9.02/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
